A Cost-Effectiveness Decision Model for Antiepileptic Drug Treatment in Newly Diagnosed Epilepsy Patients
A Systematic Review Evaluating Health-Related Quality of Life, Work Impairment, and Health-Care Costs and Utilization in Abnormal Uterine Bleeding
Eliciting Expert Opinion for Economic Models
Estimating the Rate of Accumulating Drug Resistance Mutations in the HIV Genome
Mapping from Disease-Specific Measures to Utility
Substantial Treatment Overuse in the United States?
Substantial Treatment Overuse in the United States?—Response to Grandjour
COST-EFFECTIVENESS OF ETANERCEPT AND INFLIXIMAB IN THE REAL-WORLD SETTING—AN ESTIMATE BASED ON PUBLISHED GERMAN DATA ON RESPONSE AND ADHERENCE
THE ASSOCIATION BETWEEN CO-EXISTING IMMUNE MEDIATED INFLAMMATORY DISEASES (IMID) AND HEALTH CARE COSTS IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) WHO RECEIVED ANTI-TUMOR NECROSIS FACTORS (ANTI-TNFS)
CAUSES AND EFFECTS OF SCENARIO REJECTION
METHODS FOR MEASURING DOSE ESCALATION IN TNF ANTAGONISTS FOR RHEUMATOID ARTHRITIS PATIENTS TREATED IN ROUTINE CLINICAL PRACTICE
IMPACT OF A TARGETED PATIENT COMMUNICATION ENCOURAGING GREATER GENERIC STATIN USE
MEDICATION REFILL PERSISTENCE
LONG-TERM HEALTH OUTCOMES FOR PATIENTS HOSPITALIZED WITH UNSTABLE ANGINA AND NSTEMI IN THE CALIFORNIA MEDICAID POPULATION
THE IMPACT OF A CALCIUM CHANNEL BLOCKER PREFERRED DRUG LIST ON MEDICAID PRESCRIPTION EXPENDITURES AND UTILIZATION
WHAT IF THE FEDERAL SUPPLY SCHEDULE SET PHARMACEUTICAL PRICES FOR SENIORS?
PER-PATIENT-PER-MONTH DRUG COSTS IN MEDICARE PART D PROTECTED CLASSES
CHANGES IN PRESCRIPTION USE AND OUT-OF POCKET COSTSAMONG MEDICARE ELIGIBLE ADULTS, 2005--2006
MEDICAID PREFERRED DRUG LISTS' COSTS TO PHYSICIANS
BREAST CANCER PATIENTS' PREFERENCES FOR LOCAL AND SYSTEMIC THERAPY
STANDARD GAMBLE TECHNIQUES FOR THE MEASUREMENT OF TREATMENT RELATED TOXICITY IN ONCOLOGY
REDUCED WORK LIMITATION WITH IMPROVEMENT IN MOOD, SLEEP AND VASOMOTOR SYMPTOMS IN POSTMENOPAUSAL WOMEN
ECONOMIC EVALUATION OF FEMALE VACCINATION WITH A QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE IN NEW ZEALAND
MEDICATION COMPLIANCE TO STATIN THERAPY AND ITS IMPACT ON DISEASE OUTCOMES IN TYPE 2 DIABETES
THE ASSOCIATION BETWEEN THERAPEUTIC PERSISTENCE AND NON-PHARMACY COST AMONG ANTI-TUMOR NECROSIS FACTORS (ANTI-TNFS) IN THE TREATMENT OF RHEUMATOID ARTHRITIS
PERSISTENT USE OF ANTIHYPERTENSIVE DRUGS LEADS TO A 1.5--2 TIMES INCREASED CHANCE OF BLOOD PRESSURE GOAL ATTAINMENT IN STAGE 2 ANTIHYPERTENSIVE PATIENTS
ADHERENCE TO GASTROPROTECTION AND THE RISK OF NSAID-RELATED UPPER GASTROINTESTINAL COMPLICATIONS
METHODS OF MODEL CALIBRATION
COMPARISON OF TRADITIONAL MULTIVARIABLE LOGISTIC REGRESSION AND PROPENSITY SCORE APPROACHES FOR CONTROLLING FOR TREATMENT SELECTION BIAS USING MONTE CARLO SIMULATION
CONTROLLING FOR COMORBIDITIES USING VARIATIONS OF THE CHARLSON COMORBIDITY INDEX ON MEDICARE CLAIMS DATA
TIME HORIZON BIAS IN ECONOMIC EVALUATIONS
EMPLOYEES WITH FIBROMYALGIA
IMPACT OF PATIENT COMORBIDITIES ON PHARMACOLOGICAL TREATMENT OF INSOMNIA
THE IMPORTANCE OF MODIFYING THE COURSE OF ALZHEIMER'S DISEASE
COST-UTILITY ANALYSIS EVALUATING LIDOCAINE 5% MEDICATED PLASTER RELATIVE TO GABAPENTIN FOR POST-HERPETIC NEURALGIA IN SCOTLAND
COST EFFECTIVENESS OF QUANTIFERON IN SCREENING FOR TUBERCULOSIS INFECTION IN CLOSE CONTACTS IN JAPAN
INCREMENTAL COSTS ASSOCIATED WITH ANTIBIOTICS PRESCRIBED FOR COMMUNITY ACQUIRED PNEUMONIA
THE HEALTH STATUS BURDEN OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN A U.S. MEDICARE POPULATION
IMPACT OF EARLY INITIATION OF INHALED CORTICOSTEROIDS ON RESOURCE UTILIZATION AND COSTS IN PATIENTS WITH COPD
A COST—EFFECTIVENESS ANALYSIS MODEL FOR THE SECOND LINE TREATMENT OF GASTROINTESTINAL STROMAL TUMOURS (GIST) IN MEXICO
PHARMACOECONOMIC ANALYSIS OF CAPECITABINE IN ADJUVANT TREATMENT OF STAGE III COLON CANCER IN TAIWAN
60-MONTH DATA FROM IRIS USED TO UPDATE ESTIMATES OF SURVIVAL AND COST-EFFECTIVENESS OF FIRST-LINE IMATINIB IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA
PSYCHOMETRIC VALIDATION OF A PATIENT SYMPTOM ASSESSMENT-LUNG CANCER (PSALC) INSTRUMENT FOR SMALL CELL LUNG CANCER (SCLC)
EPOETIN ALFA AND DARBEPOETIN ALFA DOSING TRENDS AND DRUG COSTS IN ELDERLY PRE-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS
OUTCOMES ASSOCIATED WITH THE USE OF THIAZOLIDINEDIONES AMONG MEDICARE BENEFICIARIES WITH TYPE II DIABETES—AN INSTRUMENTAL VARIABLE APPROACH
HEALTH CARE EXPENDITURE AND PATIENT SATISFACTION
A METHODOLOGY FOR PROJECTING DISEASE PREVALENCE, TREATMENT, AND EXPENDITURES FOR THE US EMPLOYER-INSURED POPULATION
OUTCOMES ASSOCIATED WITH THE IMPLEMENTATION OF A DOSE OPTIMIZATION PROGRAM FOR ATYPICAL ANTIPSYCHOTIC MEDICATIONS IN A MANAGED CARE ORGANIZATION
COMPARISON OF HEALTH CARE COSTS AND HOSPITALIZATION DAYS OF ELDERLY MAJOR DEPRESSIVE DISORDER PATIENTS TREATED WITH ESCITALOPRAM AND OTHER ANTIDEPRESSANTS
PREVALENCE OF LIVER DISEASES IN MEDICAID RECIPIENTS WITH SCHIZOPHRENIA
MEASURING THE INFLUENCE OF MANAGED CARE ON ANTIDEPRESSANT UTILIZATION BY CHILDREN AND ADOLESCENTS WITH DEPRESSION
ABILITY OF SF-36 AND EQ-5D TO DISCRIMINATE AMONG DISEASE ACTIVITY LEVELS IN LUPUS
PREDICTING DISEASE BURDEN IN EQ-5D US UNITS FROM SEVEN OTHER MEASUREMENT SYSTEMS (EQ-5D UK, HALEX, HUI MARK 2, HUI MARK 3, QWB-SA, SF-6D(12), SF-6D(36))
PREFERENCE VALUES FOR HEALTH STATES ASSOCIATED WITH COLON CANCER AND ITS TREATMENT
VALUING CHILDREN'S HEALTH FOR ECONOMIC EVALUATIONS
IMPACT OF MAJOR PHARMACY BENEFIT CHANGE ON DIABETES DRUG UTILIZATION
RACIAL DIFFERENCES IN EMERGENCY ROOM VISITS ASSOCIATED WITH MEDICATION USE IN MEDICAID ENROLLEES WITH TYPE 2 DIABETES
TREATMENT EFFECT ESTIMATION
RETESTING OF HEMOGLOBIN AIC AFTER OUT-OF-RANGE RESULTS
COST-EFFECTIVENESS ANALYSIS OF DARUNAVIR/R FOR HIV INFECTION IN TREATMENT-EXPERIENCED ADULTS IN THE US
MARKET STRUCTURE AND EFFECTIVENESS OF PRICE CONTROL FOR ANTIRETROVIRAL MEDICAMENTS IN COLOMBIA
THE ECONOMIC BURDEN OF VENTILATOR-ASSOCIATED PNEUMONIA DUE TO STAPHYLOCOCCUS AUREUS
ECONOMIC EVALUATION OF INFLUENZA PANDEMIC MITIGATION STRATEGIES IN THE US USING A STOCHASTIC MICROSIMULATION INFLUENZA MODEL
IMPACT OF OBESITY SEVERITY ON HEALTH CONDITIONS AND MEDICAL COSTS IN THE US
THE COST OF THE METABOLIC SYNDROME IN THE ELDERLY
CORRELATION OF WEIGHT TO CARDIOMETABOLIC RISK AS IDENTIFIED BY ICD-9 DIAGNOSIS CODES AND PRESCRIPTIONS IN PRIMARY CARE
THE RELATIONSHIP BETWEEN OBESITY AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS OR RHEUMATOID ARTHRITIS
HOSPITAL COMPLIANCE WITH ACCP GUIDELINES FOR ANTICOAGULANT THERAPY AND JCAHO PERFORMANCE MEASURES
COMPLIANCE AND PERSISTENCE WITH ASTHMA MEDICATIONS
A DECISION TREE APPROACH TO ESTIMATING COST SAVINGS OF PAY FOR PERFORMANCE PROGRAMS IN A PPO SETTING
EVALUATION OF A MULTICENTER AND MULTIDISCIPLINARY CONGESTIVE HEART FAILURE MANAGEMENT PROGRAM
MEDICATION SAFETY IN COMMUNITY PHARMACY
WASTE OF DRUGS IN TURKEY
PRESCRIPTION DRUG COST-SHARING AMONG COMMERCIALLY-INSURED CHILDREN AND ADULTS WITH CHRONIC ILLNESS
FACTORS INFLUENCING USER CHOICES TO VISIT EITHER GENERAL PRACTITIONERS OR COMMUNITY PHARMACISTS FOR MINOR AILMENTS—A DISCRETE CHOICE EXPERIMENT
WILLING TO WAIT
CHARACTERISTICS OF PATIENTS RECEIVING PHARMACEUTICAL SAMPLES AND ASSOCIATION BETWEEN SAMPLE USE AND OUT-OF-POCKET PRESCRIPTION COSTS
GENERIC-NAME PRESCRIPTION AND PERCEIVED QUALITY IN THE DEMAND FOR PHARMACEUTICALS IN ARGENTINA
RACIAL/ETHNIC DISPARITIES IN PRESCRIPTION DRUG UTILIZATION AND OUT-OF-POCKET COSTS
THE IMPACT OF MAIL ORDER PHARMACY IN DRUG UTILIZATION AND REIMBURSEMENT IN A LARGE RETIREMENT SYSTEM
ASSESSING PAYER AND EMPLOYER PERSPECTIVES RELATED TO VALUE IN HEALTH CARE
THE VOLUNTARY INCENTIVE STRUCTURE OF PEDIATRIC EXCLUSIVITY AND ITS IMPACTS ON PHARMACEUTICAL INDUSTRY BEHAVIOR AND GENERIC DRUG ENTRIES
DIFFERENCES IN CHRONIC DISEASE CARE OF PRE_MEDICARE INDIVIDUALS BETWEEN METROPOLITAN AND NON-METROPOLITAN SETTINGS
THE TRENDS IN PRESCRIBING OF HERBAL MEDICINES IN AMBULATORY SETTINGS IN THE UNITED STATES 1993--2004
POLYPHARMACY IN ELDERLY PATIENTS AT THE MEXICAN INSTITUTE OF SOCIAL SECURITY
STUDYING THE IMPACT OF CO-PAYMENT DIFFERENTIAL ON GENERIC DISPENSING RATE IN A MANAGED CARE POPULATION
COMPARING GENERIC DISPENSING RATES AMONG THREE DIFFERENT RETAIL CHANNELS
PREVALENCE OF CLINICALLY IMPORTANT POTENTIAL DRUG-DRUG INTERACTIONS IN REGIONE EMILIA ROMAGNA, ITALY
BENEFICIARY OUT-OF-POCKET
RACE AND ASSOCIATED MEDICATION ADHERENCE IN MEDICAID ENROLLED PATIENTS WITH CHRONIC DISEASE
IMPACT OF POLYPHARMACY MEDICATION THERAPY MANAGEMENT PROGRAM (MTMP) ON DRUG EXPENDITURES IN MEDICARE PART D POPULATION
DETERMINANTS OF STATE MEDICAID PER CAPITA PRESCRIPTION DRUG EXPENDITURES
HEALTH REIMBURSEMENT ACCOUNT BASED CONSUMER DRIVEN HEALTH PLANS
A NATIONAL SURVEY ON PRESCRIBERS' KNOWLEDGE OF AND THEIR SOURCE OF DRUG-DRUG INTERACTION INFORMATION
COMPARING MEDICATION ADHERENCE AND WASTAGE AMONG THREE DIFFERENT RETAIL PROGRAMS
TRENDS IN OUT OF POCKET COST BURDEN FOR PATIENTS WITH CHRONIC CONDITIONS
MORE POLICY INITIATIVES IN THE AUSTRALIAN NATIONAL REIMBURSEMENT SYSTEM THAT WILL REDUCED COSTS DRAMATICALLY
HEALTH LOCUS OF CONTROL AND USE OF CONVENTIONAL AND ALTERNATIVE CARE
ASSESSING LEVELS OF ASSOCIATION BETWEEN HEALTH CARE EXPENDITURE AND HEALTH CARE INDICATORS IN ECONOMICALLY DEVELOPED COUNTRIES
REGULATION OF DRUG EXPENDITURES IN EUROPEAN COUNTRIES
ATTITUDES OF CHAIN PHARMACY PERSONNEL TOWARD E-PRESCRIBING
EXAMINATION OF THE VALUE OF LAB DATA IN HEALTH CARE MANAGEMENT
THE STATE OF HEALTH STATUS MEASUREMENT IN LATIN AMERICA
PRELIMINARY EFFECTS OF A NEW NURSE-PHARMACIST CLINICAL PREVENTION PROGRAM ON MEDICATION USE
EXAMINING THE ASSOCIATION BETWEEN EXPOSURE RATES TO CLINICALLY IMPORTANT DRUG-DRUG INTERACTIONS AND PHARMACEUTICAL SERVICES WITHIN AMBULATORY CARE SETTING IN VETERANS AFFAIRS MEDICAL CENTERS
BREAK-EVEN COST ANALYSIS OF MEDICATION THERAPY MANAGEMENT PROGRAMS FOCUSING ON ADVERSE DRUG EVENT PREVENTION
GENERIC PRESCRIPTION AND PHYSICIANS QUALITY PERCEPTION IN ARGENTINA
THE MARKET SHARE OF PRIVATE FOR-PROFIT AND NONPROFIT HEALTH CARE PROVIDERS FROM THE HUNGARIAN HEALTH INSURANCE BUDGET
SAME-DAY DISCHARGES FROM THE HOSPITAL TO THE HOME
QUALITY ASSESSMENT OF PHARMACOECONOMIC EVALUATIONS SUBMITTED FOR REIMBURSEMENT IN KOREA
EFFECTS OF EDUCATIONAL INTERVENTION ON PRESCRIPTION WRITING IN PUBLIC AND PRIVATE HOSPITALS IN BENIN CITY, NIGERIA
PHYSICIANS' ATTITUDES TOWARD E-DETAILING
CORRELATION BETWEEN COLLEGE STUDENT ACTIVITIES AND TWO PRODUCTIVITY MEASUREMENTS
ANALYSIS OF COMMUNITY PHARMACISTS' INTERVENTIONS ON ELECTRONIC PRESCRIPTION ERRORS
PHARMACIST WORKLOAD AND PHARMACY CHARACTERISTICS ASSOCIATED WITH THE DISPENSING OF POTENTIALLY CLINICALLY IMPORTANT DRUG-DRUG INTERACTIONS
DID FDAMA SECTION 114 LEAD TO A DECLINE OF ECONOMIC-CONTENT DRUG ADVERTISING IN MEDICAL JOURNALS?
THE RELATIVE PERFORMANCE OF PHARMACEUTICAL SECTOR SECURITY PRICES DURING STOCK MARKET CRASHES
DETERMINING ANTIBIOTIC USE IN INDIA
COMPARING THE RISKS OF DEVELOPING STROKE IN UNCOMPLICATED HYPERTENSIVE PATIENTS TREATED WITH DIFFERENT ANTI-HYPERTENSIVE DRUGS
CLINICAL EXPERIENCE IN DYSLIPIDEMIC PATIENTS TREATED EITHER WITH ROSUVASTATIN 10MG/DAY OR EZETIMIBE/SIMVASTATIN 10/20 MG/DAY IN MEXICO CITY A RETROSPECTIVE ANALYSIS
HYPERTENSION MAY NOT INFLUENCE CARDIOVASCULAR BENEFITS OF STATIN THERAPY RESULTS FROM A META-REGRESSION ANALYSIS OF 69,984 PATIENTS
CUMULATIVE PERSISTENCE OF ANTIHYPERTENSIVE MEDICATION AS A NEWLY PRESCRIBED DRUG IN A MEDICAID POPULATION
NON-PERSISTENT USE OF ANTIHYPERTENSIVE DRUGS INCREASES RISK OF HOSPITALIZATIONS FOR STROKE BY NEARLY 20%
NON-PERSISTENT USE OF ANTIHYPERTENSIVE DRUGS INCREASES RISK OF HOSPITALIZATIONS FOR ACUTE MYOCARDIAL INFARCTION BY 10% IN PATIENTS WITH LOW OR INTERMEDIATE CARDIOVASCULAR RISK
RELATIONSHIPS BETWEEN VENOUS THROMBOEMBOLIC (VTE) PROPHYLACTIC TREATMENTS AND VTE COMPLICATIONS OR THROMBOCYTOPENIA AND AMONG VETERANS RECEIVING TOTAL HIP REPLACEMENTS
RISK OF MYOPATHY ASSOCIATED WITH THE USE OF STATINS AND POTENTIALLY INTERACTING MEDICATIONS-- A RETROSPECTIVE ANALYSIS
ISOLATED SYSTOLIC HYPERTENSION IN A COHORT OF INNER CITY MINORITY PATIENTS
CLINICAL OUTCOME OF HYPERTENSION MANAGEMENT
THE EFFECTS OF SEASONAL VARIATIONS AND WEATHER CONDITIONS ON THE OCCURRENCE OF HEART ATTACKS IN HUNGARY BETWEEN 2000–2004
SEASONAL VARIATIONS OF THE OCCURRENCE OF ACUTE MYOCARDIAL INFARCTION IN HUNGARY BETWEEN 2000--2004
METABOLIC SYNDROME PREVALENCE IN A HYPERTENSIVE POPULATION
SURVIVAL ANALYSIS OF PATIENTS WITH ACUTE MYOCARDIAL INFARCTION ACCORDING TO HOSPITAL TYPE
NEW DIAGNOSIS OF HYPERTENSION AMONG CELECOXIB AND NON-SELECTIVE NSAID USERS
AN ECONOMIC ASSESSMENT OF THE CONTROL AND DETENTION PROGRAMS IN HYPERTENSIVE MEXICAN POPULATION (2005–2025)
COMPARING THE COST OF MICROSURGERY AND RADIOSURGERY FOR THE MANAGEMENT OF VESTIBULAR SCHWANNOMA
PERIPHERAL ARTERIAL DISEASE IN DIABETIC PATIENTS
COST COMPARISON OF DIFFERENT TREATMENTS FOR DEEP VEIN THROMBOSIS PROPHYLAXIS DURING ABDOMINAL SURGERY
A COST-EFFECTIVENESS STUDY COMPARING IVABRADINE WITH STANDARD CARE IN STABLE ANGINA PECTORIS IN THE NETHERLANDS
ECONOMIC EVALUATION OF EPLERENONE COMPARED WITH PLACEBO IN PATIENTS WITH MYOCARDIAL INFARCTION COMPLICATED BY LEFT VENTRICULAR SYSTOLIC DYSFUNCTION AND HEART FAILURE IN MEXICO
A CARDIOVASCULAR DISEASE COST-EFFECTIVENESS MODEL BASED ON CTT META-ANALYSIS
EVALUATION OF DYSLIPIDEMIA THERAPIES FOR TREATMENT OF LOW HDL AND HIGH LDL
USE OF A DECISION ANALYTIC MODEL TO EVALUATE COST PER PATIENT TREATED TO GOAL WITH HIGH POTENCY ANTILIPIDEMICS
THE ECONOMIC AND HEALTH CONSEQUENCES IN MEXICO OF MANAGING HYPERTENSION AND HYPERCHOLESTEROLEMIA WITH A SINGLE PILL THERAPY
COST-EFFECTIVENESS OF ROSUVASTATIN AND EZETIMIBE/SIMVASTATIN IN PATIENTS WITH DYSLIPIDEMIA IN MEXICO CITY
CLINICAL AND ECONOMIC BURDEN OF NONADHERANCE TO LIPID-LOWERING AND ANTIHYPERTENSIVE THERAPY IN A HYPERTENSIVE POPULATION
A COST--EFFECTIVENESS ANALYSIS FOR PROPHYLACTIC THERAPIES AGAINST AIR TRAVELER THROMBOSIS
PHARMACOECONOMIC ANALYSIS OF EXTENDED PROPHYLAXIS BY ENOXAPARIN AFTER HIP JOINT REPLACEMENT
COST-EFFECTIVENESS AMONG BRAND AND GENERIC STATINS BASED ON REAL-WORLD EFFECTIVENESS
COST-EFFECTIVENESS OF ACHIEVING ADDITIONAL LIPID TARGETS WHEN SUBSTITUTING FENOFIBRATE 145 MG FOR STANDARD FENOFIBRATE THERAPY
IMPACT OF DEPRESSION ON HEALTH STATUS AND HEALTH CARE UTILIZATION IN PATIENTS WITH HYPERTENSION
ANALYSIS OF CLOPIDOGREL USE IN OUTPATIENT SETTINGS
COST OF CONSUMABLES ASSOCIATED WITH CARDIOVASCULAR COMPUTED TOMOGRAPHY ANGIOGRAPHY
IMPACT OF NESIRITIDE ON TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE (ADHF)
THE EFFECT OF DRUG COST-SHARING ON ADHERENCE TO CHRONIC MEDICATIONS
THE IMPACT OF CARE GAP IN MANAGING HIGH CARDIOVASCULAR RISK PATIENTS
TREATMENT OF DEPRESSION IN CORONARY ARTERY DISEASE
TRENDS IN THE OFF-LABEL PRESCRIBING OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A (HMG-COA) REDUCTASE INHIBITORS IN THE UNITED STATES
UTILIZATION AND COMPLIANCE OF CALCIUM CHANNEL BLOCKERS IN THE TREATMENT OF HYPERTENSION IN THE LOUISIANA MEDICAID PROGRAM
USE OF RECOMMENDED MEDICATIONS AFTER MYOCARDIAL INFARCTION IN AUSTRIA
PREDICTORS OF CLOPIDOGREL THERAPY PERSISTENCE IN ACUTE CORONARY SYNDROME PATIENTS
EFFECTS OF MEDICAID ACCESS RESTRICTIONS ON STATIN UTILISATION FOR PATIENTS TREATED BY PHYSICIANS PRACTISING IN POOR AND MINORITY NEIGHBORHOODS
ARE MINORITIES MORE LIKELY TO BE INITIALLY DIAGNOSED OF HYPERTENSION DURING NON-OFFICE-BASED VISITS? EVIDENCE FROM MEDICAL EXPENDITURE PANEL SURVEY 1996--2003
EFFECT OF MENTAL DISORDERS ON HEALTH CARE COST AMONG ELDERLY WITH DISEASES OF THE HEART
BURDEN OF ILLNESS AMONG PATIENTS AT HIGH RISK FOR MAJOR CARDIOVASCULAR EVENTS
PCV48 IMPACT OF MEDICAID PREFERRED DRUG LISTS ON THERAPEUTIC ADHERENCE
DEVELOPMENT OF AN INTERACTIVE MODEL TO PREDICT LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL) REDUCTION AND LDL GOAL ATTAINMENT ASSOCIATED WITH STATIN USE IN ROUTINE CLINICAL PRACTICE
PROCEDURAL MIX AND VOLUME DURING THE FIRST YEAR OF OWNERSHIP OF A COMPUTED TOMOGRAPHY ANGIOGRAPHY SCANNER
THE IMPACT OF SIMVASTATIN LAUNCHING ON EXISTING LIPITOR PATIENTS IN A MANAGED CARE SETTING
PROFILES OF INITIAL DRUG THERAPIES AMONG NEWLY DIAGNOSED HYPERTENSIVE PATIENTS WITH NO COMPELLING INDICATIONS
PROJECTED COST SAVINGS COMPARISON TO MANAGED CARE ORGANIZATIONS FOR THE YEAR FOLLOWING GENERIC SIMVASTATIN AND PRAVASTATIN AVAILABILITY IN THE US
BLOOD PRESSURE CONTROL THROUGH PATIENT AND PHYSICIAN EDUCATION PROGRAMS
THE COST--EFFECTIVENESS LANDSCAPE OF GENETIC TESTING WITH WARFARIN THERAPY
HOW INFLUENTIAL ARE CLINICAL GUIDELINES FOR THE EVALUATION OF ACUTE CARDIAC SYMPTOMS? METHODOLOGY FOR THE INVESTIGATION OF NATIONAL CORONARY DISEASE IDENTIFICATION (INCIDENT)
HOSPITAL POLICIES FOR TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE
EFFECTIVENESS OF OUTPATIENT CLOPIDOGREL TREATMENT IN PREVENTING CARDIOVASCULAR EVENTS IN PATIENTS UNDERGOING STENTING FOR ACS
THE CLIN-O-GRAM
DIFFERENCES IN ANTIBIOTICS PRESCRIBED BY PHYSICIANS WITH HIGH AND LOW INFECTION RATES APPLIED TO PATIENTS UNDERGOING CARDIOVASCULAR SURGERY
ASSESSING SYSTEMATIC DIFFERENCES IN PHYSICIAN'S TENDENCY TO REPORT ROUNDED BLOOD PRESSURE MEASUREMENTS
DYNAMIC OPTIMIZATION IN THE TREATMENT OF HYPERLIPIDEMIA
FACTOR SCREENING FOR PARSIMONY OF VARIABLES IN PHARMACOECONOMIC MODELS
DRUG-DRUG INTERACTIONS ON ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR PRESCRIPTIONS IN THE UNITED STATES
MODELED ACHIEVEMENT OF OPTIMAL LIPID VALUES AND ASSOCIATED CARDIOVASCULAR EVENT RATES WITH EXTENDED-RELEASE NIACIN/SIMVASTATIN, EZETIMIBE/SIMVASTATIN, AND INDIVIDUAL AGENTS IN A MANAGED CARE POPULATION
USING AN INTERNATIONAL DATABASE OF ACUTE CORONARY EVENTS TO ASSESS TODAY'S PRACTICE PATTERNS AND DESCRIBE TREATMENT STRATEGIES IN THE HOSPITAL SETTING
IS META-ANALYSIS ALWAYS A GOOD IDEA?
BLOOD PRESSURE SUCCESS ZONE LONGITUDINAL STUDY OF SUCCESS (BPSZ-BLISS). AN OBSERVATIONAL, MULTI-CENTER STUDY OF THE IMPACT OF THE BPSZ EDUCATIONAL PROGRAM ON BLOOD PRESSURE CONTROL, PERSISTENCE, COMPLIANCE, AND TREATMENT SATISFACTION. DESIGN AND METHODS
MOBILE PHONE MESSAGE VERSUS POSTAL REMINDERS TO INCREASE TREATMENT ADHERENCE AFTER LIPID LOWERING THERAPY AMONG HYPERLIPIDEMIC PATIENTS IN PRIMARY CARE
THE IMPACT OF INTERACTIVE VOICE RECOGNITION TECHNOLOGY ON ADHERENCE TO STATIN THERAPY
CHARACTERIZATION OF HYPERTENSIVE PATIENTS WHO MIGHT BENEFIT FROM A COMBINATION OF TWO DRUGS IN ONE PILL FOR REDUCTION OF CARDIOVASCULAR RISK
DESCRIBING DRUG USE PATTERNS USING SEQUENCE ANALYSIS
DEVELOPMENT AND VALIDATION OF THE HEALTH-RELATED QUALITY OF LIFE (HRQL) COMPONENT OF THE HYBRID INSTRUMENT-IMPACT (IMPACT OF PHARMACIST ACTIVITIES AND CARE ON TREATMENT OUTCOMES)
LINGUISTIC VALIDATION OF THE KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE IN 30 LANGUAGES
RECENT TRENDS IN OBESITY-RELATED CO-MORBIDITIES AND MEDICAL COSTS IN THE US
GLYCAEMIC AND WEIGHT EFFECTS OF EXENATIDE FOR DIFFERENT AGE GROUPS
A RETROSPECTIVE EVALUATION OF HBA1C GOAL ATTAINMENT AMONG VARIOUS DIABETES TREATMENT REGIMENS IN A MANAGED CARE POPULATION
THE EFFECTIVENESS OF DANCE THERAPY AMONG ADULT PATIENTS WITH DIABETES MELLITUS TYPE II
BODY WEIGHT GAIN EXPERIENCED BY DIABETIC PATIENTS DUE TO THIAZOLIDINEDIONES (TZDS)
RACIAL DIFFERENCES IN HOSPITALIZATIONS ASSOCIATED WITH MEDICATION USE IN MEDICAID ENROLLEES WITH TYPE 2 DIABETES
BUDGET IMPACT ANALYSIS OF PIOGLITAZONE FOR DIABETES IN TAIWAN
COSTBENEFIT ANALYSIS OF INHALED INSULIN
DIRECT AND INDIRECT COSTS AND RESOURCE UTILIZATION ASSOCIATED WITH PHOTOCOAGULATION AND VITRECTOMY PROCEDURES AMONG EMPLOYEES WITH DIABETIC RETINOPATHY
A PHARMACOECONOMIC EVALUATION FOR THE TREATMENT OF MEXICAN PATIENTS WITH DIABETES TYPE 2
THE COST-EFFECTIVENESS OF VACUUM ASSISTED CLOSURE® (V.A.C.) THERAPY FOR THE TREATMENT OF DIABETIC FOOT WOUNDS
RESOURCE UTILIZATION AND ECONOMIC COST OF CARE BASED ON A RANDOMIZED TRIAL OF V.A.C.® THERAPY IN THE TREATMENT OF DIABETIC FOOT ULCER WOUNDS
COPAYMENT LEVEL AND MEDICATION ADHERENCE IN TYPE 2 DIABETES PATIENTS MANAGED WITH INSULIN ASPART PEN THERAPY
ECONOMIC OUTCOMES ASSOCIATED WITH SWITCHING TO INSULIN PEN THERAPY IN MEDICAID TYPE 2 DIABETES PATIENTS
TREATMENT COSTS ATTRIBUTABLE TO OVERWEIGHT/OBESE IN PATIENTS WITH DIABETES MELLITUS IN THE U.S.ADULT POPULATION
EMERGENCY ROOM CARE FOR DIABETES MELLITUS IN THE UNITED STATES
DETERMINATION OF HEALTH CARE COSTS INCURRED BY SWEDISH PATIENTS WITH TYPE 2 DIABETES
PDB18 THE RELATIVE COST EFFECTIVENESS OF INSULIN GLARGINE VERSUS NPH INSULIN USING UK REAL LIFE DATA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
RELATIVE COST EFFECTIVENESS OF INSULIN GLARGINE VERSUS NPH INSULIN USING UK REAL LIFE DATA IN TYPE 1 DIABETES MELLITUS
COMPARISON OF ROSIGLITAZONE VERSUS PIOGLITAZONE INTRODUCTION AND ASSOCIATED HEALTH CARE UTILIZATION IN TYPE 2 DIABETES MEDICAID ENROLLEES
PRICE AND UTILIZATION OF ORAL ANTI-DIABETIC MEDICATIONS FROM 1991 TO 2005 IN U.S. MEDICAID PROGRAMS
INFLUENCE OF HEMOGLOBIN AIC TEST RESULT ON DECISION TO INITIATE INSULIN SUPPLEMENTATION IN TYPE 2 DIABETES
IMPACT OF PATIENT EDUCATION ON HBA1C REDUCTION IN DIABETIC PATIENTS WITH CONCOMITANT HYPERTENSION
PRELIMINARY VALIDATION OF THE COGNITIVE DISTRESS, FATIGUE, HYPERGLYCEMIA AND HYPOGLYCEMIA SUBSCALES OF THE DIABETES SYMPTOM CHECKLIST REVISED (DCSR) FOR USE IN CLINICAL TRIALS INVOLVING PATIENTS WITH TYPE 1 OR TYPE 2 DIABETES
HEALTH STATUS AND QUALITY OF LIFE IN TYPE 2 DIABETES MELLITUS
CAN PATIENTS ACCURATELY RATE THEIR ADHERENCE TO MEDICATIONS?
MEDICATION ADHERENCE IN PATIENTS WITH DIABETES DURING THE MEDICARE PART D BENEFIT COVERAGE GAP PERIOD
IMPACT OF INITIATING OR CONVERTING TO TREATMENT WITH AN INSULIN ASPART ANALOG PEN ON MEDICATION ADHERENCE IN TYPE 2 DIABETES PATIENTS ON VIAL/SYRINGE INSULIN
RELATIONSHIP BETWEEN EATING HEALTHY FOODS AND REGULAR EXERCISE AND PHYSICAL HEALTH, MENTAL HEALTH, AND HEALTH STATUS IN TYPE II DIABETICS
HEALTH RELATED QUALITY OF LIFE ON BODY MASS INDEX FOR PEOPLE WITH TYPE 2 DIABETES IN THE GENERAL ADULT POPULATION IN ENGLAND
HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PRIMARY CARE PATIENTS WITH TYPE 2 DIABETES MELLITUS AND DEPRESSION
HEALTH-RELATED QUALITY OF LIFE AND UTILITIES OF RESPONDENTS WITH TYPE 2 DIABETES COMPARED TO THOSE WITH DIFFERING LEVELS OF CARDIOMETABOLIC RISK
VALIDATION OF THE 25-ITEM NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE (VFQ-25) IN PATIENTS WITH DIABETIC RETINOPATHY
EFFECT OF INSULIN GLARGINE AND NPH INSULIN ON QUALITY OF LIFE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
ESTIMATING HEALTH-RELATED QUALITY OF LIFE FROM HYPOGLYCEMIA ELICITED FROM NON-DIABETIC AND DIABETIC RESPONDENTS IN CANADA
DIFFERENCES IN EQ-5D SCORES FOR US AND UK-BASED PREFERENCE SCORING SYSTEMS IN PEOPLE WITH TYPE 2 DIABETES MELLITUS
ESTIMATING THE QALY BENEFITS OF TREATMENT FOR GROWTH HORMONE DEFICIENCY (GHD) IN ADULT PATIENTS
CHANGES IN COMORBIDITIES, MEDICATION USE AND TREATMENT COSTS AFTER DIAGNOSIS OF GENERALIZED ANXIETY DISORDER
DIVALPROEX SODIUM VERSUS VALPROIC ACID
ANTIDEPRESSANT PROPHYLAXIS FOR POST-STROKE DEPRESSION
ADVERSE EVENT PROFILE ASSOCIATED WITH OFF-LABEL USE OF ANTIPSYCHOTIC MEDICATIONS
A COMPARISON OF TREATMENT-EMERGENT DIABETES AMONG ATYPICAL AND TYPICAL ANTIPSYCHOTIC USERS
SUICIDALITY AND ANTIDEPRESSANTS USE IN CHILDREN AND ADOLESCENTS
FORECASTING U.S. MEDICAID PROGRAM EXPENDITURE ON ANTIDEPRESSANT DRUGS
NET BENEFIT ANALYSIS OF DIVALPROEX SODIUM EXTENDED-RELEASE COMPARED TO VALPROIC ACID IN THE TREATMENT OF BIPOLAR DISORDER
COST-EFFECTIVINESS ANALYSIS OF LONG ACTING MICROSPHERES OF RISPERIDONE (RISPERDAL CONSTA) IN THE TREATMENT OF SCHIZOPHRENIA IN MEXICO
MEDICATION USE PATTERNS AND COSTS ASSOCIATED WITH ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF BIPOLAR DISORDER
DEPRESSED INDIVIDUALS WITH MUSCULOSKELETAL CHRONIC PAIN AND HEADACHE SHOW HIGHER HEALTH CARE UTILIZATION AND COSTS
COST-EFFECTIVENESS ANALYSIS OF SINGLE-DOSE EXTENDED RELEASE METHYLPHENIDATE (CONCERTA®) VS. ATOMOXETINE AND SHORT-ACTION METHYLPHENIDATE, FOR THE MANAGEMENT OF ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY IN MEXICO
COST-EFFECTIVENESS ANALYSIS OF GALANTAMINE (REMINYL ER) IN THE TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEMIER'S TYPE IN MEXICO
PMH15
PREDICTORS OF HIGH COSTS FOR GENERALIZED ANXIETY DISORDER WITH OR WITHOUT PAIN
TREATMENT COSTS OF COMORBID GENERALIZED ANXIETY DISORDER, DEPRESSION AND PAIN
INCREMENTAL MEDICAID EXPENDITURES ASSOCIATED WITH DEMENTIA
A COMPARISON OF TOTAL DIRECT MEDICAL COSTS TO MANAGED CARE OF ESCITALOPRAM VERSUS VENLAFAXINE XR TREATMENT IN MAJOR DEPRESSIVE DISORDER
THE ECONOMIC COSTS TO MANAGED CARE ORGANIZATIONS OF EXCESS MD WITHDRAWAL FROM DULOXETINE TREATMENT
ANALYSIS OF DRUG TREATMENT PATTERNS, SERVICE USE AND COSTS ASSOCIATED WITH SPECIFIC PHARMACOLOGICAL TREATMENTS FOR MAJOR DEPRSSIVE DISORDER
HEALTH CARE COSTS AND RESOURCE USE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
ECONOMIC EVALUATION OF LONG ACTING TREATMENTS FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER IN THE MILITARY HEALTH SYSTEM
36-MONTH COST-UTILITY ANALYSIS OF ANTIPSYCHOTIC TREATMENTS IN PATIENTS WITH SCHIZOPHRENIA IN THE PAN-EUROPEAN SOHO (SCHIZOPHRENIA OUTPATIENT HEALTH OUTCOMES) STUDY
PREDICTORS OF BIPOLAR DISORDER IN PATIENTS DIAGNOSED WITH MAJOR DEPRESSION IN A PRIVATELY INSURED POPULATION
ACCESS TO ILLICT DRUGS
STIMULANT UTILIZATION IN CHILDREN UNDER A STATE EMPLOYEES BENEFIT PROGRAM
PMH28
ECONOMIC BURDEN OF ALCOHOLISM AND ALCOHOL ABUSE IN A US MANAGED--CARE SETTING
HEALTH CARE BURDEN OF PATIENTS WITH ALCOHOL DEPENDENCE SYNDROME
DRUG COST DEVELOPMENT OF CITALOPRAM AND FLUOXETINE FOLLOWING THE INTRODUCTION OF GENERIC SUBSTITUTION IN FINLAND
HEALTH SERVICE AND PRESCRIPTION DRUG USE AND COSTS AMONG HISPANIC AND NON-HISPANIC CAUCASIAN SUBJECTS WITH ADHD
PROFILING UTILIZATION PATTERNS OF ANTIPSYCHOTICS AMONG PATIENTS WITH BIPOLAR DISORDER
PHARMACOLOGIC TREATMENT OF GENERALIZED ANXIETY DISORDER WITH COMORBID DEPRESSION AND PAIN CONDITIONS
TREATMENT INITIATION WITH ATOMOXETINE VS. STIMULANTS FOR ADULTS WITH ADHD IN MEDICAID SETTINGS
DISEASE PROGRESSION IN ALZHEIMER'S DISEASE PATIENTS TREATED WITH A CHOLINESTERASE INHIBITOR IN CLINICAL PRACTICE
TREATMENT PERSISTENCE AND COMPLIANCE WITH GALANTAMINE ER
ASSESSING PERSISTENCE OF ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA
A MULTI-DOMAIN MICRO-SIMULATION ECONOMIC MODELING FRAMEWORK IN ALZHEIMER'S DISEASE
12-MONTH TREATMENT DISCONTINUATION RATES IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH RISPERIDONE LONG ACTING INJECTION (RLAI)
RISPERIDONE LONG ACTING INJECTION (RLAI) IN THE TREATMENT OF EARLY VERSUS LATE DIAGNOSIS PATIENTS WITH SCHIZOPHRENIA INTERIM RESULTS FROM OBSERVATIONAL STUDIES CONDUCTED IN SPAIN, AUSTRALIA AND BELGIUM
IMPACT OF ALTERNATIVE CENSORING SPECIFICATIONS ON TIME-TO-EVENT ANALYSES COMPARING ALTERNATIVE MEDICATIONS
SWITCHING OF ANTIPSYCHOTICS AMONG STABLE AND UNSTABLE SCHIZOPHRENIA PATIENTS
PMH44 THE PREDICTIVE VALIDITY OF DIFFERENT ADHERENCE MEASURES USING ADMINISTRATIVE CLAIMS DATA
PMH45 SOCIODEMOGRAPHIC AND CLINICAL CORRELATES OF UTILITY SCORES IN ALZHEIMERS DISEASE
PMH46 NOVEL USE OF A TELEPHONE BASED INTERACTIVE VOICE RESPONSE SYSTEM TO IMPROVE DATA COLLECTION
PMH47 THE EFFECTS OF PATIENT TYPE ON PHYSICAL AND MENTAL HEALTH OF CAREGIVERS IN FRANCE, GERMANY, ITALY, SPAIN AND THE UNITED KINGDOM
PMH48 PREFERENCE AND WILLINGNESS-TO-PAY STUDY TO ASSESS THE VALUE OF ATOMOXETINE USING DISCRETE CHOICE ANALYSIS
ASSESSING THE NET CLINICAL BENEFIT AND ABSOLUTE RISK REDUCTION OF DISEASE MODIFYING DRUGS IN RELAPSING REMITTING MULTIPLE SCLEROSIS
SAFETY AND IMMUNOGENICITY OF REBIF® NEW FORMULATION (RNF) A NEW SUBCUTANEOUS FORMULATION OF INTERFERON BETA-1A 44 MCG THREE TIMES WEEKLY
THE BUDGETARY IMPACT OF THE UTILIZATION OF NATALIZUMAB FOR THE TREATMENT OF RELAPSING MULTIPLE SCLEROSIS
RESOURCE UTILIZATION PATTERNS WITH TOPIRAMATE FOR MIGRAINE PREVENTION IN THE MANAGED CARE SETTING
DOES SPECIALTY CARE OF SPINA BIFIDA PATIENTS INFLUENCE COST OF CARE?
COST-EFFECTIVENESS OF SCREENING FOR COGNITIVE IMPAIRMENT IN OLDER POPULATIONS
PHARMACOECONOMIC ANALYSIS OF ANTIEPILEPTIC DRUGS IN THE TREATMENT OF THE IDIOPATHIC GENERALIZED EPILEPSIES
COST-EFFECTIVENESS OF PREGABALIN AND OTHER ADDON ANTIEPILEPTIC DRUG THERAPIES IN PATIENTS WITH REFRACTORY PARTIAL EPILEPSY IN ARGENTINA
THE COST-EFFECTIVENESS OF NATALIZUMAB IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
AN ANALYSIS OF THE HEALTH AND PRODUCTIVITY BURDEN OF INSOMNIA AND ITS TREATMENT
LIFETIME CLINICAL AND ECONOMIC CONSEQUENCES OF CHANGES IN BODY WEIGHT ASSOCIATED WITH MIGRAINE HEADACHE PROPHYLAXIS WITH TOPIRAMATE VERSUS AMITRIPTYLINE
IMPACT OF RELAPSES ON TOTAL COSTS OF CARE FOR PATIENTS WITH MULTIPLE SCLEROSIS
HEALTH CARE COSTS AND UTILIZATION FOR ALZHEIMER'S DISEASE PATIENTS
ECONOMIC CONSEQUENCES OF THERAPEUTIC ALTERATION IN THE MANAGEMENT OF INSOMNIA
ECONOMIC CONSEQUENCES OF GENERIC SUBSTITUTION FOR ANTIEPILEPTIC MEDICATION
ASSOCIATION OF LONG-TERM MIGRAINE PREVENTIVE MEDICATION USE AND RESOURCE UTILIZATION/PRODUCTIVITY LOSS
PREVALENCE OF NON-ADHERENCE TO PARKINSON'S DISEASE MEDICATIONS AND ITS IMPACT ON SYMPTOM PROGRESSION IN A MEDICARE POPULATION
DETERMINANTS OF EMERGENCY DEPARTMENT UTILIZATION FOR MIGRAINE CARE
DEVELOPING A MIGRAINE QUALITY OF CARE MEASUREMENT SET
UNDERSTANDING LIMITATIONS OF PATIENT REPORTED CLINICAL OUTCOMES IN LUPUS
PRODUCT ENHANCEMENTS DECREASE THE INCIDENCE OF INJECTION SITE REACTIONS AND PAIN RESULTING IN IMPROVED ADHERENCE TO THERAPY IN PATIENTS WITH MULTIPLE SCLEROSIS
IMPLICATIONS OF COMORBIDITY ON COSTS FOR PATIENTS WITH ALZHEIMER'S DISEASE
PSYCHOMETRIC EVALUATION OF FIVE MIGRAINE SPECIFIC HEALTH RELATED QUALITY OF LIFE INSTRUMENTS
MEDICATION SIDE-EFFECTS AND ADHERENCE AMONG PATIENTS WITH MULTIPLE SCLEROSIS
A REVIEW OF HEALTH RELATED QUALITY OF LIFE INSTRUMENTS USED IN CHILDREN AND ADOLESCENTS WITH EPILEPSY
MEASUREMENT OF QUALITY OF LIFE IN RESTLESS LEGS SYNDROME
DETECTION OF DIFFERENTIAL ITEM FUNCTIONING BETWEEN ENGLISH AND CHINESE VERSIONS OF THE PDQ-8
PSYCHOMETRIC EVALUATION OF OBSTRUCTIVE SLEEP APNEA SPECIFIC HEALTH RELATED QUALITY OF LIFE INSTRUMENTS
THE IMPACT OF RESTLESS LEGS SYNDROME ON VARIOUS DIMENSIONS OF LIFE
COMORBIDITIES, ECONOMIC AND HUMANISTIC FACTORS ASSOCIATED WITH MIGRAINE
THE IMPACT OF CHRONIC INSOMNIA ON PRODUCTIVITY IN THE US, FRANCE, AND JAPAN
THE CONNECTION BETWEEN 5 YEARS MORTALITY FOLLOWING FEMORAL NECK FRACTURE AND ITS RISK FACTORS
KAPLAN-MEIER SURVIVAL ANALYSIS OF PATIENTS WITH DISPLACED AND NON-DISPLACED FEMORAL NECK FRACTURE OVER 60
A COST-EFFECTIVENESS ANALYSIS OF RHBMP-2 IN SPINE FUSION SURGERY IN SWEDEN AND DENMARK
INPATIENT COSTS AND OUTCOMES ASSOCIATED WITH TRAUMATIC INJURY IN THE UNITED STATES BY INJURY SEVERITY AND TRAUMA CENTER DESIGNATION
POI5
WOMEN TREATED WITH MONTHLY IBANDRONATE DEMONSTRATE IMPROVED PERSISTENCE VERSUS WEEKLY BISPHOSPHONATES
WOMEN ARE MORE PERSISTENT WITH MONTHLY IBANDRONATE VS. WEEKLY BISPHOSPHONATES
CAN THE SF-36 PHYSICAL FUNCTION SCALE CAPTURE FUNCTIONAL OUTCOMES DURING RECOVERY FROM TRAUMATIC INJURY? A REVIEW OF THE LITERATURE
COST EFFECTIVENESS OF THE USE OF INFLIXIMAB COMPARED TO OTHER BIOLOGICAL AGENTS (BA) IN THE SYSTEMIC TREATMENT OF MODERATE TO SEVERE PSORIASIS
THE HEALTH CARE AND WORK LOSS COSTS ASSOCIATED WITH ATOPIC DERMATITIS
THE DIRECT AND INDIRECT COST BURDEN ASSOCIATED WITH SEBORRHEIC DERMATITIS
FREQUENCY AND COST CONSEQUENCES ASSOCIATED WITH FAILURE OF MUPIROCIN AMONG UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS (USSSI)
QUALITY OF DERMATOLOGIC CARE DELIVERED BY PHYSICIAN ASSISTANTS
THE IMPACT OF PSORIASIS ON HEALTH CARE COSTS AND WORK LOSS
A LONG TERM COST-EFFECTIVENESS ANALYSIS MODEL FOR SMOKING CESSATION IN MEXICO
THE COST UTILITY OF VARENICLINE IN SMOKING CESSATION HEALTH PROGRAMMES IN SWEDEN
ESTIMATING THE INCIDENCE AND PREVALENCE OF SMOKING RELATED MORBIDITIES USING PROXY VALUES
CONSUMER PERCEPTION OF SELF-AID MATERIALS IN OVER-THE-COUNTER NICOTINE PATCH
A RETROSPECTIVE COMPARATIVE ANALYSIS OF TREATMENT OUTCOMES OF ALPHA-BLOCKERS IN THE MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA WITHIN A MANAGED CARE POPULATION
OUTCOMES AND COSTS ASSOCIATED WITH IMMUNOSUPPRESSION COMPLIANCE
RISK FACTORS ASSOCIATED WITH MEDICATION NONADHERENCE AMONG RENAL TRANSPLANT RECIPIENTS
HAEMOGLOBIN FLUCTUATIONS IN HAEMODIALYSIS PATIENTS RECEIVING INTRAVENOUS EPOETIN ALFA OR INTRAVENOUS DARBEPOETIN ALFA
FLUCTUATIONS IN HAEMOGLOBIN LEVELS IN PREDIALYSIS AND PERITONEAL DIALYSIS PATIENTS RECEIVING INTRAVENOUS EPOETIN ALFA OR INTRAVENOUS DARBEPOETIN ALFA
IMPACT OF AN INCREMENTAL INCREASE IN PERITONEAL DIALYSIS UTILIZATION ON HOSPITAL BUDGETS IN COLOMBIA
GENERIC SUBSTITUTION OF TACROLIMUS AFTER RENAL TRANSPLANTATION
COST EFFECTIVENESS OF ICODEXTRINE-BASED SOLUTIONS IN END STAGE RENAL DISEASE PATIENTS UNDERGOING PERITONEAL DIALYSIS THERAPY
A RETROSPECTIVE MATCHED COHORT STUDY OF THE BURDEN OF SECONDARY HYPERPARATHYROIDISM (SHPT) IN PREDIALYSIS PATIENTS WITHOUT VITAMIN D RECEPTOR (VDR) ACTIVATOR THERAPY
COST ANALYSIS OF PRE-DIALYSIS CHRONIC KIDNEY DISEASE
MEDICAL AND WORK PRODUCTIVITY COSTS BEFORE AND AFTER DIAGNOSIS OF ANEMIA IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) PATIENTS
THE COST-EFFECTIVENESS OF MYCOPHENOLATE MOFETIL (MMF) AS FIRST-LINE THERAPY IN ACTIVE LUPUS NEPHRITIS
PANEL DATA ANALYSIS SHOWS PERITONEAL DIALYSIS TO BE NEGATIVELY ASSOCIATED WITH HOSPITALIZATION AT THE STATE LEVEL
ANEMIA-RELATED TREATMENT VARIATIONS IN WOMEN WITH CHRONIC KIDNEY DISEASE IN US OUTPATIENT SETTINGS
DRUG UTILIZATION AND COSTS OF ERYTHROPOIETIC AGENTS IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE
ASSESSMENT OF ADHERENCE WITH IMMUNOSUPPRESSANT MEDICATIONS IN TRANSPLANT PATIENTS AND THE POTENTIAL COST SAVINGS ASSOCIATED WITH INCREASED ADHERENCE
STRESS URINARY INCONTINENCE
LINGUISTIC VALIDATION OF THE NOCTURIA QUALITY OF LIFE (N-QOL) QUESTIONNAIRE IN 10 LANGUAGES
LINGUISTIC VALIDATION OF THE ICIQ MALE SEXUAL MATTERS ASSOCIATED WITH LOWER URINARY TRACT SYMPTOMS QUESTIONNAIRE (ICIQ-MLUTSSEX) IN 7 LANGUAGES
IMPACT OF SOLIFENACIN ON QUALITY OF LIFE, MEDICAL CARE USE, WORK PRODUCTIVITY, AND HEALTH UTILITY IN THE ELDERLY
RELATIONSHIP BETWEEN MEASURES OF ASTHMA CONTROL AND COMBINATION THERAPY TREATMENT REGIMENS IN SEVERE OR DIFFICULT-TO-TREAT ASTHMA
EXACERBATION RATES FOR SINGLE VS. DUAL CONTROLLER THERAPY FOR MILD-PERSISTENT ASTHMA
EVALUATION OF RISK FACTORS AND PREDICTORS OF HEALTH OUTCOMES AMONG PERSONS WITH ASTHMA
ADVERSE DRUG REACTIONS IN ECONOMIC EVALUATIONS
ECONOMIC EVALUATION OF SYMBICORT® (BUDESONIDE/FORMOTEROL) MAINTENANCE AND RELIEVER THERAPY IN ASTHMA (SMART) COMPARED TO FIXED DOSE COMBINATION STRATEGIES
ECONOMIC EVALUATION OF A NEW AIRWAY INFLAMMATION MONITOR IN THE DIAGNOSIS AND MANAGEMENT OF ASTHMA IN THE US
PHARMACOECONOMIC OUTCOMES OF LEVALBUTEROL AND RACEMIC ALBUTEROL IN HOSPITALIZED PATIENTS REQUIRING NEBULIZATION THERAPY (POLARIS)
QUALITY-ADJUSTED LENGTH OF STAY ANALYSIS OF HOSPITALIZED PATIENTS WITH ASTHMA OR COPD TREATED WITH LEVALBUTEROL OR RACEMIC ALBUTEROL
A 4-YEAR ASSESSMENT OF SEVERE AND NON-SEVERE ASTHMA IN A REAL-WORLD SETTING
ALLERGY IMMUNOTHERAPY
A 4-YEAR ASSESSMENT OF SUB-ACUTE LACK OF ASTHMA CONTROL IN A REAL-WORLD SETTING
PAA12
CATEGORIES AND TRANSITION PATTERNS OF GUIDELINE INFORMED CONTROL IN SEVERE OR DIFFICULT-TO-TREAT ASTHMA
PRESCRIPTION DRUG INSURANCE COVERAGE
AGREEMENT BETWEEN PARENT REPORTS AND MEDICAL CHARTS FOR PEDIATRIC ASTHMA MEDICATION UTILIZATION
PREDICTORS OF THE PRESCRIBING OF ASTHMA PHARMACOTHERAPY IN THE AMBULATORY PATIENT POPULATION OF THE UNITED STATES
PARENTS OF ASTHMATIC CHILDREN WERE ACCURATE REPORTERS OF URGENT HEALTH SERVICES USE—A RETROSPECTIVE AGREEMENT ANALYSIS
DATA EXTRACTION METHODS, ECONOMETRIC MODELING AND FACTORIAL ANALYSIS REVEAL CLINICALLY IMPORTANT PATIENT PROFILES IN CHRONIC ASTHMA
THE EVOLUTION OF ASTHMA GUIDELINES FOR CHILDREN
IMPACT OF ADHERENCE TO INHALED CORTICOSTEROID ON HEALTH CARE UTILIZATION
IS CURE WORSE THAN THE DISEASE?
CAN PATIENTS WITH ASTHMA FEEL THEIR MAINTENANCE INHALER WORKING RIGHT AWAY? REPRODUCIBILITY AND VALIDITY OF A WEEKLY DIARY FOR ASSESSING PERCEPTION AND SATISFACTION
UNDERSTANDING PATIENT PERCEPTION OF THERAPY
ASTHMA CONTROL AND HEALTH-RELATED QUALITY OF LIFE IN CHILDREN
IMPACT OF ALLERGIC RHINITIS ON WORK PRODUCTIVITY
SOCIOECONOMIC FACTORS RELATED TO ASTHMA CONTROL IN CHILDREN
MORTALITY RATE OF PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIASIS, CROHN'S DISEASE AND ULCERATIVE COLITIS IN THE UNITED KINGDOM
COST OF PAIN THERAPY FOR OSTEOARTHRITIS IN A PRIVATELY INSURED POPULATION IN THE UNITED STATES
COST-EFFECTIVENESS OF LUMIRACOXIB COMPARED TO CELECOXIB FOR THE TREATMENT OF OSTEOARTHRITIS IN CANADA
ECONOMIC EVALUATION OF TUMOR NECROSIS FACTOR INHIBITORS IN THE TREATMENT OF ANKYLOSING SPONDYLITIS
COST-EFFECTIVENESS OF EXTENDED-RELEASE AND IMMEDIATE-RELEASE TRAMADOL FOR THE TREATMENT OF CHRONIC OSTEOARTHRITIS PAIN
A COMPARISON OF HEALTH CARE COSTS IN PATIENTS WITH PSORIATIC ARTHRITIS (PSA) WHO RECEIVED ETANERCEPT (ETA), ETA PLUS METHOTREXATE (MTX), INFLIXIMAB (INF), OR INF PLUS MTX
EVALUATION OF PHARMACOLOGIC TREATMENTS OVER 30 MONTHS FOR OSTEOARTHRITIS USING A NATIONAL MANAGED CARE DATABASE
NEW AUDIENCE FOR PATIENT-REPORTED OUTCOMES (PRO) DATA PATIENTS
IMPACT OF PATIENT'S OUT-OF-POCKET COST ON ADHERENCE AND PERSISTENCE WITH BIOLOGIC THERAPIES FOR RHEUMATOID ARTHRITIS
MANAGEMENT OF RHEUMATOID ARTHRITIS—FINDINGS FORM A CLAIMS DATABASE ANALYSIS
ECONOMIC EVALUATION OF BIOLOGIC RESPONSE MODIFIER SPECIALTY PHARMACY PRIOR AUTHORIZATION PROGRAM
INCREASE IN ECONOMIC BURDEN OF HIP AND KNEE REPLACEMENTS IN THE UNITED STATES
TUMOR NECROSIS FACTOR INHIBITORS—A PHARMACOECONOMIC REVIEW OF ITS USE IN ANKYLOSING SPONDYLITIS
UTILIZATION OF CHRONIC ARTHRITIS-RELATED HEALTH CARE SERVICES BY CHILDREN AND ADOLESCENTS IN A MEDICAID POPULATION
USING MIXED TREATMENT COMPARISONS AND META-REGRESSION TO PERFORM INDIRECT COMPARISONS TO ESTIMATE THE EFFICACY OF BIOLOGIC TREATMENTS IN RHEUMATOID ARTHRITIS
A COMPARISON OF SWITCHING PATTERNS AMONG ANTI-TUMOR NECROSIS FACTORS (ANTI-TNFS) IN THE TREATMENT OF RHEUMATOID ARTHRITIS
A COMPARISION OF THERAPEUTIC PERSISTENCE AMONG ANTI-TUMOR NECROSIS FACTORS (ANTI-TNFS) IN THE TREATMENT OF RHEUMATOID ARTHRITIS
A FIVE-YEAR LONGITUDINAL ANALYSIS COMPARING DOSE CHANGES FOR PATIENTS WITH RHEUMATOID ARTHRITIS TAKING INFLIXIMAB IN A MEDICARE AND IN A COMMERCIALLY INSURED POPULATION
ARTHRITIS AND HEALTH-RELATED QUALITY OF LIFE AMONG ADULTS IN OHIO
COLONIC STENTING VERSUS SURGERY FOR MALIGNANT LARGE BOWEL OBSTRUCTION
ASSESSING THE NET HEALTH OUTCOMES OF A 4D ELECTROMAGNETIC TUMOR TRACKING SYSTEM DURING RADIOTHERAPY FOR CLINICALLY LOCALIZED PROSTATE CANCER
CORRELATION BETWEEN TIME TO PROGRESSION AND OVERALL SURVIVAL IN PATIENTS WITH METASTATIC BREAST CANCER
BUDGET IMPACT ANALYSIS OF ADJUVANT THERAPY WITH TRASTUZUMAB FOR HER2-POSITIVE EARLY BREAST CANCER IN POLISH SETTING
PHARMACOECONOMIC ANALYSIS OF SORAFENIB AND SUNITINIB FOR FIRST LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) COMPARED WITH COMBINATION THERAPY OF BEVACIZUMAB, GEMCITABINE, AND CAPECITABINE (BGC) AT A LARGE CANCER CENTER
A COST-EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY WITH EXEMESTANE, ANASTROZOLE, LETROZOLE OR TAMOXIFEN IN POSTMENOPAUSAL WOMEN WITH EARLY-STAGE BREAST CANCER IN MEXICO
COST-EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY WITH TRASTUZUMAB FOR HER2-POSITIVE EARLY BREAST CANCER IN POLISH SETTING
COST-EFFECTIVENESS OF ANASTROZOLE VERSUS TAMOXIFEN FOR THE TREATMENT OF POST MENOPAUSAL HORMONE-RECEPTOR POSITIVE BREAST CANCER (BC) IN THE ADJUVANT SETTING IN BRAZIL
PRIMARY PROPHYLAXIS OF FEBRILE NEUTROPENIA WITH PEGFILGRASTIM IS COST-EFFECTIVE COMPARED WITH SECONDARY PROPHYLAXIS FOR WOMEN WITH EARLY-STAGE BREAST CANCER RECEIVING CHEMOTHERAPY
COST-EFFECTIVENESS OF BREAST CANCER RISK ASSESSMENT IN PRIMARY CARE
IS EARLY REPLACEMENT OF HORMONE THERAPY (HT) BY SEQUENTIAL CHEMOTHERAPY (CT) COST-EFFECTIVE IN HORMONE-RECEPTOR (HR) POSITIVE ADVANCED BREAST CANCER (ABC)?
COLORECTAL CANCER
COST-EFFECTIVENESS ANALYSIS OF DOCETAXEL VERSUS OTHER REGIMENS IN THE ADJUVANT THERAPY OF EARLY AND LOCALLY ADVANCED BREAST CANCER IN POLAND
PHARMACOECONOMIC ANALYSIS OF TREATING ADVANCED GASTRIC CANCER (AGC) WITH CAPECITABINE/CISPLATIN (XP) VS. 5-FU/CISPLATIN (FP) REGIMENS IN AN ITALIAN SETTING
COST-EFFECTIVENESS OF NEW TARGETED THERAPY SUNITINIB MALATE AS SECOND LINE TREATMENT IN METASTATIC RENAL CELL CARCINOMA IN ARGENTINA
THE RELATIONSHIP BETWEEN SHORT-TERM RESPONSE AND LONG-TERM OUTCOMES IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA
MEDICAL COST CONSIDERATIONS OF FIXED DOSING REGIMENS OF ERYTHROPOIETIC AGENTS IN PATIENTS WITH CHEMOTHERAPY-INDUCED ANEMIA
BURDEN OF ILLNESS ANALYSIS OF MALIGNANT METASTATIC MELANOMA IN THE UNITED STATES
TREND ANALYSIS OF UTILIZATION AND MARKET-SHARE COMPETITION FOR BREAST CANCER MEDICATIONS IN US MEDICAID PROGRAMS FROM 1991 TO 2005
COST-OF-ILLNESS
DRUG UTILIZATION, COST CONSIDERATIONS AND TRANSFUSION PATTERNS FOR ERYTHROPOIETIC STIMULATING AGENTS IN A MANAGED CARE CANCER POPULATION
FIRST-LINE TREATMENT AND LIFETIME MEDICAL-CARE COSTS AMONG ELDERLY STAGE IIIB/IV NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH COMMONLY USED DOUBLET THERAPIES
IDENTIFICATION OF PATIENTS WITH SMALL CELL LUNG CANCER (SCLC) AND COST ASSESSMENT OF INTRAVENOUS (IV) CHEMOTHERAPY IN CLAIMS DATA
CHARACTERIZING RESOURCE USE AND TREATMENT COSTS FOR CHRONIC MYELOGENOUS LEUKEMIA (CML) IN THE UNITED STATES (US)
REAL-WORLD EPOETIN ALFA (EPO) AND DARBEPOETIN ALFA (DARB) DOSING AND COST CONSIDERATIONS IN ELDERLY HOSPITAL INPATIENTS
FIRST-, SECOND- AND THIRD-LINE CHEMOTHERAPY FOR NONSMALL CELL LUNG CANCER
AN ANALYSIS OF COSTS ASSOCIATED WITH ADMINISTRATION OF TRASTUZUMAB-BASED COMBINATION IV THERAPIES IN METASTATIC BREAST CANCER PATIENTS IN A US POPULATION
A MARKOV MODEL EVALUATING THE COST-UTILITY OF A 4D REAL-TIME ELECTROMAGNETIC TRACKING SYSTEM (CALYPSO® 4D LOCALIZATION SYSTEM WITH BEACON TRANSPONDERS) IN THE LOCALIZATION OF PROSTATE TUMORS DURING RADIOTHERAPY
PCN29
A COST—UTILITY ANALYSIS MODEL FOR THE SECOND LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN MEXICO
SYSTEMATIC REVIEW OF TREATMENTS/INTERVENTIONS AND QALY IN BREAST CANCER PATIENTS
COST-UTILITY ANALYSIS OF DOCETAXEL VERSUS OTHER REGIMENS IN THE NEOADJUVANT THERAPY OF LOCALLY ADVANCED BREAST CANCER IN POLAND
ANALYSIS OF DRUG REQUIREMENT FOR TREATMENT ADVANCED HODGKIN'S DISEASE
ANALYSIS OF DOSE, COST AND USE PATTERNS OF ERYTHROPOIETIN STIMULATING AGENTS IN CANCER PATIENTS
OUTPATIENT USE OF HEMATOPOIETIC COLONY STIMULATING FACTORS (CSF) AMONG ELDERLY CANCER PATIENTS WITH CHEMOTHERAPY
NEW SYSTEM OF COSTLY DRUG REIMBURSEMENT IN FRANCE
FREQUENCY AND DISTRIBUTION OF CERVICAL SCREENING SMEARS IN HUNGARY
WITHIN COUNTRY DIFFERENCES IN MAMMOGRAPHY COVERAGE OF THE HUNGARIAN NATIONWIDE ORGANIZED BREAST CANCER SCREENING PROGRAMME
GAP BETWEEN INPATIENT TREATMENT COST OF AND MORTALITY DUE TO BREAST CANCER IN HUNGARY
PATTERNS OF TREATMENT OF NON SMALL CELL LUNG CANCER (NSCLC) IN COMMUNITY PRACTICE
DRUG COST CONSIDERATIONS FOR ERYTHROPOIETIC STIMULATING THERAPIES (ESTS) AGENTS IN PATIENTS INITIATED AT FDA-APPROVED DOSING
A MULTI-PART EVALUATION OF A CANCER SYMPTOM MANAGEMENT INFORMATION TECHNOLOGY SYSTEM
ADHERENCE TO GUIDELINES FOR USE OF ERYTHROPOIESIS STIMULATING PROTEINS IN PATIENTS WITH CHEMOTHERAPY-INDUCED ANEMIA
INTEGRATION OF QUALITY OF LIFE WITH SURVIVAL FOR COMPARATIVE HEALTH OUTCOME ASSESSMENT
A PRACTICAL AND USEFUL COMBINATION OF MEASURES FOR ASSESSING THE COST-UTILITY OF TWO MAJOR TREATMENT STRATEGIES FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN CHILDHOOD
ESTIMATING THE NUMBER NEEDED TO VACCINATE FROM A MARKOV MODEL OF GENITAL WARTS, CERVICAL PRECANCER AND CANCER
EVALUATION OF FACTOR STRUCTURE AND RELIABILITY OF THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY—KIDNEY SYMPTOM INDEX
STANDARD GAMBLE TECHNIQUES FOR THE MEASUREMENT OF TREATMENT RELATED TOXICITY IN ONCOLOGY
LINGUISTIC VALIDATION OF THE FACT-HEAD AND NECK IN 8 LANGUAGES FOR INDIA
CHALLENGES AND LIMITATIONS OF IDENTIFYING PRESCRIPTION TREATMENT PATTERNS FOR PATIENTS WITH METASTATIC BREAST CANCER USING COMMERCIALLY INSURED CLAIMS DATABASES
METHODS AND APPLICATION OF DATA COLLECTION TECHNOLOGY IN THE ELECTRONIC VELCADE® OBSERVATIONAL STUDY (EVOBS)
COMPARISON OF IMPACT OF ELEVEN TYPES OF ADVANCED CANCER ON QUALITY OF LIFE
A COMPARISION OF THE PSYCHOMETRICS PROPERTIES OF HEALTH RELATED QUALITY OF LIFE INSTRUMENTS USED IN GLIOBLASTOMA MULTIFORME PATIENTS
HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH AXITINIB (AG-013736)
TRANSLATION AND CULTURAL ADAPTATION OF HEALTH UTILITIES INDEX (HUI) FOR ASSESSING EFFECTS OF NEUTROPENIA AMONG PEDIATRIC ONCOLOGY PATIENTS IN TURKEY
RELATIONSHIP BETWEEN FUNCTIONAL STATUS AND SELF RATED HEALTH IN PATIENTS WITH PROSTATE CANCER
PATIENT REPORTED OUTCOMES IN LABELING FOR ONCOLOGY PRODUCTS
COMPARISON OF TOPICAL CIPROFLOXACIN/DEXAMETHASONE OTIC SUSPENSION VERSUS POLYMYXIN B/NEOMYCIN/HYDROCORTISONE OTIC SUSPENSION FOR THE TREATMENT OF ACUTE OTITIS EXTERNA
PREVALENCE OF GLAUCOMATOUS RISK FACTORS IN PATIENTS FROM A MANAGED-CARE SETTING
THE ECONOMIC BURDEN OF GLAUCOMA-RELATED VISUAL IMPAIRMENT
INCREMENTAL COSTS ASSOCIATED WITH ANTIBIOTICS PRESCRIBED FOR ACUTE OTITIS MEDIA
A COST-BENEFIT ANALYSIS OF THE SN60WF ASPHERIC INTRAOCULAR LENS
THE RELATIVE COST-EFFECTIVENESS OF MULTIFOCAL INTRAOCULAR LENSES
EFFECTIVENESS AND COSTS OF PROSTAGLANDINS, WITH CAI OR AN ALPHA-2 AGONIST, IN THE TREATMENT OF GLAUCOMA
EFFECTIVENESS AND COSTS OF BETA-BLOCKERS WITH CAI OR ALPHA-2 FOLLOWING GLAUCOMA TREATMENT FAILURE
EFFECTIVENESS AND COSTS OF TRAVATAN VS XALACOM AS FIRST-LINE TREATMENT FOR GLAUCOMA AN ANALYSIS PERFORMED ON THE UK GENERAL PRACTITIONER RESEARCH DATABASE
COST OF BLINDNESS IN THE CZECH REPUBLIC
COST OF STANDARD CARE TREATMENT IN PATIENTS WITH PROGRESSION OF PRIMARY OPEN ANGLE GLAUCOMA
IMPACT OF PNEUMOCOCCAL CONJUGATE VACCINE ON ACUTE OTITIS MEDIA IN YOUNG CHILDREN IN THE UNITED STATES, 1997--2004
ADJUNCTIVE THERAPY USE BY GLAUCOMA PATIENTS ON ORAL ANTIHYPERTENSIVES
PEY14
THE IMPACT OF PHARMACOTHERAPY COMPLIANCE ON HEALTH CARE CHARGES IN PATIENTS WITH PRIMARY OPEN-ANGLE GLAUCOMA
DEPRESSIVE SYMPTOMATOLOGY, MEDICATION PERSISTENCE, AND ASSOCIATED HEALTH CARE COSTS IN OLDER ADULTS WITH GLAUCOMA
MULTIPLE METHODS TO ESTIMATE THE MINIMAL CLINICALLY IMPORTANT DIFFERENCE OF THE OCULAR SURFACE DISEASE INDEX®
COMORBIDITIES DURING THE YEAR FOLLOWING DIAGNOSIS FOR PERSONS WITH AND WITHOUT GERD USING THE AGENCY FOR HEALTH RESEARCH AND QUALITY (AHRQ) 261 SPECIFIC CATEGORIES
BIOLOGICAL AGENTS FOR THE MANAGEMENT OF CROHN'S DISEASE IN ADULTS
CONSTIPATION IN PERSONS RECEIVING HOSPICE CARE
INCLUSION OF A PENTAVALENT ROTAVIRUS VACCINE IN THE NEW ZEALAND CHILDHOOD IMMUNISATION SCHEDULE
PHARMACOECONOMICS OF CHRONIC HEPATITIS C IN SLOVAKIA
BURDEN OF POST-OPERATIVE ILEUS (POI) IN COLECTOMY SURGERY PATIENTS IN THE UNITED STATES
HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH CONSTIPATION (C-ONLY) AND CO-OCCURRING IRRITABLE BOWEL SYNDROME AND CONSTIPATION (IBS+C) COMPARED TO MIGRAINE IN A LARGE MANAGED CARE POPULATION
COST OF PATIENT CARE IN PATIENTS WITH CROHN'S DISEASE IN BRAZIL
INCORPORATING NON-ADHERENCE RESULTING FROM MULTIPLE DAILY DOSE REGIMENS INTO ECONOMIC MODELS
RELATIONSHIP BETWEEN GASTROESOPHAGEAL REFLUX DISEASE SYMPTOMS AND COSTS
HAVING YOUR CAKE AND EATING IT TOO
LOWER DISEASE ACTIVITY AND CLINICAL REMISSION ARE ASSOCIATED WITH REDUCED HOSPITALIZATION RISK IN CROHN'S DISEASE
ONE WEEK VERSUS DAILY RECALL OF SYMPTOMS OF INFANT GERD
MENTAL AND PHYSICAL FUNCTIONING REDUCED AMONG PATIENTS WITH FREQUENT ATYPICAL GERD SYMPTOMS
VALIDATION OF GASTROINTESTINAL QUALITY OF LIFE INDEX FOR ASSESSMENT OF GALLSTONE-RELATED SYMPTOMS
SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE, CONCOMITANT DISEASES, HEALTH-RELATED QUALITY OF LIFE AND WORK PRODUCTIVITY
GASTROESOPHAGEAL REFLUX DISEASE AND HEALTH-RELATED QUALITY OF LIFE IN THE GENERAL POPULATION OF SHANGHAI, CHINA
A COMPARISON OF INPATIENT OUTCOMES BETWEEN SICKLE CELL DISEASE AND NON-SICKLE CELL DISEASE PATIENTS UNDERGOING HIGH-VOLUME SURGICAL PROCEDURES
STUDY OF ANEMIA IN LONG-TERM CARE (SALT)
ANEMIA IN LONG-TERM CARE PATIENTS
THE ASSOCIATION BETWEEN CONCOMITANT MEDICATIONS USE AND THROMBOEMBOLIC COMPLICATIONS IN ELDERLY VETERANS UNDERGOING MAJOR ORTHOPEDIC SURGERY
RESTROSPECTIVE STUDY OF OUTCOMES AND COSTS IN SICKLE CELL DISEASE (SCD) PATIENTS IN US
LIFETIME ECONOMIC VALUE OF ORTHOPEDIC SURGERY WITH RECOMBINANT ACTIVATED FACTOR VII IN HEMOPHILIA PATIENTS WITH INHIBITORS
COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA DOSES ROUTINELY USED IN CLINICAL PRACTICE IN DEPARTMENT OF DEFENSE BENEFICIARIES
ESTIMATING UTILITY VALUES FOR SELF-REPORTED JOINT PAIN AND MOTION LIMITATION OUTCOMES IN ADULT HEMOPHILIA PATIENTS-THE HEMOPHILIA UTILIZATION GROUP STUDY-PART V (HUGS-V)
THE ASSOCIATION OF BARRIERS TO CARE AND HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH FACTOR VIII DEFICIENCY-THE HEMOPHILIA UTILIZATION GROUP STUDY-PA RT V (HUGS-V)
EVALUATION OF CAUSES AND CONSEQUENCES OF INJURIES IN CHILDREN
E-PRESCRIBING REDUCES BEERS PRESCRIBING AMONG THE ELDERLY
COST-EFFECTIVENESS OF ORAL AND TRANSDERMAL CONTRACEPTIVE METHODS
THE DIRECT AND INDIRECT COST BURDEN OF TREATED UTERINE FIBROIDS
SURGICAL COST OF PELVIC ORGAN PROLAPSE IN GERMANY, FRANCE AND ENGLAND
CONTRACEPTIVE AND NON-CONTRACEPTIVE BENEFITS OF A LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM IN A VERTICALLY INTEGRATED HMO
CHARACTERISTICS ASSOCIATED WITH BENZODIAZEPINE USAGE IN ELDERLY OUTPATIENTS IN TAIWAN
MEDICARE PART D AND STATE-LEVEL VARIATIONS IN MEDICARE ADVANTAGE PARTICIPATION
PATIENT GENDER AND ASSOCIATED MEDICATION ADHERENCE IN AN OLDER POPULATION WITH CHRONIC DISEASES
BURDEN OF PREMENSTRUAL DYSPHORIC DISORDER ON HEALTH-RELATED QUALITY OF LIFE
QUALITY-OF-LIFE WEIGHTS FOR THE U.S. POPULATION
IDENTIFYING MEANINGFUL IMPROVEMENTS IN VASOMOTOR SYMPTOMS AMONG MENOPAUSAL WOMEN USING DESVENLAFAXINE SUCCINATE
COST-EFFECTIVENESS OF ACUTE AND CHRONIC RHINOSINUSITIS AT THE MEXICAN INSTITUTE OF SOCIAL SECURITY (IMSS)
RETROSPECTIVE COMPARISON OF TREATMENT OUTCOMES AMONG HEPATITIS C PATIENTS TREATED WITH PEGYLATED INTERFERON 2A OR 2B PLUS RIBAVIRIN AT DIFFERENT VA MEDICAL CENTERS
TREATMENT FAILURE, COMPLICATIONS AND COSTS OF LEVOFLOXACIN VS. AMOXICILLIN/CLAVULANATE ANTIBIOTIC THERAPY IN OUTPATIENT COMMUNITY ACQUIRED PNEUMONIA (CAP)
TREATMENT FAILURE AMONG COMMUNITY ACQUIRED PNEUMONIA (CAP) PATIENTS TREATED WITH LEVOFLOXACIN OR MACROLIDES IN AN OUTPATIENT SETTING
CLINICAL AND ECONOMIC OUTCOMES OF VANCOMYCIN FOR GRAM-POSITIVE INFECTIONS IN AN ERA OF INCREASING RESISTANCE
INITIATION OF ANTIVIRAL THERAPY AMONG CHRONIC HEPATITIS C PATIENTS ENROLLED IN MEDICAID
PREVALENCE OF CACHEXIA (WASTING SYNDROME) DIAGNOSIS AND TREATMENT AMONG PATIENTS WITH HIV/AIDS
BURDEN OF HERPES ZOSTER AND HEALTH AND BUDGET IMPACT OF A VACCINATION PROGRAM
LENGTH OF STAY AND COSTS ASSOCIATED WITH SURGICAL SITE INFECTIONS IN COLON PROCEDURES IN A LARGE U.S. DATABASE
ANALYSIS OF INCIDENCE, RESOURCE USE AND COSTS OF SEVERE SEPSIS IN BRAZIL AND THE ECONOMIC IMPACT OF DROTRECOGIN-ALFA ACTIVATED
COST-EFFECTIVENESS OF SUBSTITUTING LAMIVUDINE (LVD) WITH ENTECAVIR (ETV) IN CHRONIC HEPATITIS B (CHB) PATIENTS IN THE PUBLIC SECTOR OF HONG KONG
THE COST-EFFECTIVENESS ANALYSIS OF ENTECAVIR IN THE TREATMENT OF CHRONIC HEPATITIS B (CHB) PATIENTS IN POLAND
COST-EFFECTIVENESS OF LINEZOLID IN GRAM-POSITIVE INFECTIONS
A CANADIAN COST-EFFECTIVENESS ANALYSIS OF DARUNAVIR FOR HIV INFECTION IN TREATMENT-EXPERIENCED ADULTS
COST EFFECTIVENESS OF MF59 ADJUVANTED INFLUENZA VACCINE IN FRANCE
COST-EFFECTIVENESS ANALYSIS OF IMMUNIZATION STRATEGIES FOR THE CONTROL OF MENINGOCOCCAL INFECTIOUS DISEASE
COST-EFFECTIVENESS OF PNEUMOCOCCAL VACCINATION (PCV) FOR INFANTS WITH THE 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HONG KONG
PHARMACOECONOMIC EVALUATION OF HERD IMMUNITY CONFERRED BY SEVEN-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PREVNAR®) IN CANADA BASED ON CALGARY REGION EPIDEMIOLOGICAL DATA
COST-EFFECTIVENESS OF GARGLING FOR PREVENTION OF UPPER RESPIRATORY TRACT INFECTIONS
PHARMACOECONOMIC ANALYSIS OF SEVERE COMMUNITY-ACQUIRED PNEUMONIA TREATMENT
THE CLINICAL AND ECONOMIC BURDEN OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS DUE TO STAPHYLOCOCCUS AUREUS
IMPACT OF S. AUREUS INFECTIONS ON EXPENDITURES AND LENGTH-OF-STAY IN U.S. HOSPITALS
DETERMINANTS OF TOTAL HOSPITAL COSTS AMONG INPATIENTS WITH CANDIDEMIA
THE ECONOMIC IMPACT OF METHICILLIN RESISTANCE IN STAPHYLOCOCCUS AUREUS BACTEREMIA IN KOREA
DIRECT COSTS OF ANEMIA AMONG PATIENTS TREATED WITH ZIDOVUDINE
IMPACT OF HIV AND HCV CO-INFECTION ON HOSPITALIZATION AND RESOURCE USE AMONG HEMOPHILIA ENROLLEES IN COMMERCIAL HEALTH PLANS
USING DECISION SIMULATION MODEL TO EVALUATE THE COST EFFECTIVENESS OF ENTECAVIR COMPARED TO ADEFOVIR THERAPY IN LAMIVUDINE REFRACTORY CHRONIC HEPATITIS B (CHB) PATIENTS
BUDGET IMPACT AND UTILISATION OF ANTIBIOTICS WITHIN SLOVAKIA
DRUG PRICE, UTILIZATION AND SPENDING FOR ANTIRETROVIRAL MEDICATIONS IN U.S. MEDICAID PROGRAMS FROM 1991 TO 2005
SMOKING STATUS AND PNEUMONIA IMMUNIZATION
PATTERNS OF ANTIVIRAL THERAPY USE AMONG CHRONIC HEPATITIS C PATIENTS ENROLLED IN MEDICAID
ANALYSES FROM ROUTINE PATIENT CARE SETTINGS FOR CLINICAL RESEARCH PURPOSES
ESTIMATING THE GDP SAVED DUE TO AIDS TREATMENT
PIN34
COST-EFFECTIVENESS ANALYSIS OF PALIVIZUMAB FOR RESPIRATORY SYNCYTIAL VIRUS INFECTION IN HIGH-RISK INFANTS IN JAPAN
MICROSIMULATION OR COHORT MODELING? A COMPARATIVE CASE STUDY IN HIV INFECTION
LESSONS LEARNED IN EVALUATING THE IMPACT OF VACCINES ON HEALTH CARE UTILIZATION IN TWO LARGE RANDOMIZED CLINICAL TRIALS
ASSESSING THE ASSOCIATION BETWEEN COMPLIANCE AND THERAPEUTIC FAILURE FOR ANTIRETROVIRAL DRUGS IN HIV POSITIVE PATIENTS
CULTURAL ADAPTATION AND VALIDATION OF A HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE (HRQOL) FOR ENGLISH-SPEAKING HEPATITIS B PATIENTS IN SINGAPORE
SURVEY OF CHRONIC PAIN IN TURKEY
COGNITIVE FUNCTION IN CHRONIC NON-MALIGNANT PAIN PATIENTS TREATED WITH EXTENDED-RELEASE MORPHINE SULFATE (AVINZA®)
ESTIMATED COSTS ASSOCIATED WITH DIFFERENT FRACTURE RISKS RELATED TO OPIOID TREATMENT IN GERMANY
ECONOMICS OF MORPHINE EQUIVALENT DAILY DOSES (MEDD)
COST-EFFECTIVENESS ANALYSIS OF THE FIXED COMBINED ORAL TREATMENT WITH TRAMADOL/ACETAMINOPHEN (TRAMACET®) FOR THE MANAGEMENT OF LOWER BACK PAIN AT THE IMSS (MEXICAN INSTITUTE OF SOCIAL SECURITY)
A COST MINIMIZATION ANALYSIS OF IV BOLUS VERSUS IV INFUSION DICLOFENAC IN POST-OPERATIVE PAIN
THE SPECTRUM OF HEALTH CARE COSTS ASSOCIATED WITH HERPES ZOSTER
OUT-OF-POCKET PRICES OF OPIOID ANALGESICS IN THE UNITED STATES
COSTS AND COMORBIDITIES IN LOWER BACK PAIN PATIENTS USING NARCOTIC MEDICATIONS
COSTS ATTRIBUTABLE TO INTRAVENOUS PATIENT CONTROLLED ANALGESIA
COSTS OF ERRORS ATTRIBUTABLE TO INTRAVENOUS PATIENT CONTROLLED ANALGESIA—FOCUS ON MEDICATION-RELATED ERRORS
PETS, PEOPLE AND DEMAND FOR ETODOLAC IN THE UNITED STATES OF AMERICA
OFF-LABEL OPIOID USE IN THE TREATMENT OF CHRONIC PAIN
EXAMINING FAMILY PHYSICIANS' ATTITUDES AND WILLINGNESS TO PRESCRIBE LONG-ACTING OPIOIDS TO PATIENTS WITH MODERATE TO SEVERE CHRONIC NONMALIGNANT PAIN
PRESCRIBING OF FENTANYL PATCHES TO NON-OPIOID TOLERANT PATIENTS IN THE MILITARY HEALTH SYSTEM (MHS)
QUANTIFYING HEALTH RELATED QUALITY OF LIFE IN A CHRONIC PAIN POPULATION
SYSTEMATIC OVERVIEW OF THE PSYCHOMETRIC PROPERTIES OF THE BRIEF PAIN INVENTORY IN MALIGNANT AND NON-MALIGNANT PAIN
VALIDATION OF INGUINAL PAIN QUESTIONNAIRE
BURDEN OF CONCOMITANT ASTHMA AND COPD IN A MEDICAID POPULATION
CLINICAL OUTCOMES OF PATIENTS HOSPITALIZED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) EXACERBATIONS IN SINGAPORE
DIRECT AND INCREMENTAL COSTS OF ACUTE RESPIRATORY INFECTIONS BY INITIATING ANTIBIOTIC
AN ECONOMIC EVALUATION OF FIRST LINE ANTIBIOTICS FOR THE INPATIENT TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS IN MEXICO
COST—EFFECTIVENESS ANALYSIS OF FIRST LINE ANTIBIOTICS FOR THE INPATIENT TREATMENT OF PATIENTS WITH COMMUNITY ACQUIRE PNEUMONIA IN A PUBLIC MEXICAN HOSPITAL
EVALUATING THE COST-EFFECTIVENESS OF TIOTROPIUM IN THE TREATMENT OF MODERATE CHRONIC OBSTRUCTIVE PULMONARY DISEASE
COMPARISON OF EVENTS (HOSPITALIZATIONS AND EMERGENCY DEPARTMENT VISITS) AND COSTS FOR MEDICAID PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) BY INITIAL MEDICATION REGIMEN
ASSESSING TREATMENT EFFECTS OF INHALED CORTICOSTEROID ON MEDICAL COSTS AMONG COPD PATIENTS
ESTIMATED COST SAVINGS ASSOCIATED WITH THE USE OF A NEW TASTE-MASKED ORAL CLARITHROMYCIN PREPARATION FOR THE TREATMENT OF RESPIRATORY TRACT INFECTIONS IN CHILDREN IN GERMANY
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
PERCEPTIONS ABOUT BEHIND-THE-COUNTER AVAILABILITY OF PSEUDOEPHEDRINE
PROPENSITY OF PRESCRIBING FLUTICASONE/SALMETEROL COMBINATION IN A HIGH RISK MEDICAID POPULATION
EPIDEMIOLOGY AND ECONOMIC BURDEN OF STROKE-RELATED RISK FACTORS
HOSPITAL-BASED OUTCOMES ASSOCIATED WITH NON-TRAUMATIC SUBARACHNOID HEMORRHAGE
THE IMPACT OF WIDESPREAD ACCESS TO ORGANIZED STROKE CARE IN CANADA
COST-EFFECTIVENESS OF RECOMBINANT ACTIVATED FACTOR VII IN THE TREATMENT OF INTRACEREBRAL HEMORRHAGE OVER A TWO-YEAR MANAGED CARE ENROLLMENT PERIOD
PROMOTING THE IMPROVEMENT OF STROKE CARE AT THE STATE-LEVEL
GENERIC AND DISEASE-SPECIFIC HEALTH RELATED QUALITY OF LIFE (HRQOL) IN STROKE SURVIVORS
DOES ADMINISTRATION MODE AFFECT ITEM HIERARCHY IN STROKE SPECIFIC QUALITY OF LIFE MEASURE, STROKE IMPACT SCALE?—TELEPHONE AND MAIL ADMINISTRATION METHODS
COST OF COMPLICATIONS ASSOCIATED WITH TOTAL KNEE REPLACEMENT AND TOTAL HIP REPLACEMENT
COSTEFFECTIVENESS ANALYSIS OF RHBMP-2 IN THE TREATMENT OF OPEN TIBIA FRACTURES IN SWEDEN AND DENMARK
SAVINGS OF THE USE OF RHBMP-2 IN OPEN TIBIA FRACTURES FOR EUROPEAN HEALTH CARE SYSTEMS FROM A PAYER AND SOCIETAL PERSPECTIVE
FORECASTING WITH TIME SERIES MODELS TO EXAMINE THE AVAILABILITY OF INPATIENT BEDS
THE EFFECT OF PHARMACIST CONSULTATION ON PATIENT MEDICATION ADHERENCE
DEVELOPING NATIONS AND COST-EFFECTIVENESS
EVALUATING AN ONLINE CALCULATOR FOR ANALYZING INCREMENTAL NET BENEFIT AND THE EXPECTED VALUE OF PERFECT INFORMATION FROM PATIENT LEVEL DATA
A COST-EFFECTIVENESS STUDY OF TRANSPORTING PERSONS WITHOUT MEDICAL NEEDS BY AMBULANCE.A PROSPECTIVE STUDY OF AMBULANCE SERVICE IN SWEDEN
A PRE-POST TIME IN MOTION METHODOLOGY TO EXAMINE PRODUCT WASTAGE REDUCTION
CREATING KNOWLEDGE ABOUT ADVERSE DRUG REACTIONS
DEVELOPMENT OF PHARMACOECONOMIC ANALYSIS IN THE RUSSIAN FEDERATION
RELIABILITY AND COMPLETENESS OF MEDICAID ENROLLMENT DATA
APPLICATION OF ZERO INFLATED POISSON MODEL FOR ESTIMATING FUNCTIONS OF COST AND EFFECTIVENESS IN COUNT DATA
PMC12 PRICE VS ACCESS
JOINT DETERMINATION OF PRICES, RESEARCH EXPENDITURE AND MARKETING EXPENDITURE BY PHARMACEUTICAL FIRMS
PREDICTORS OF SELF-RATED HEALTH STATUS AMONG GENERAL POPULATION IN THE UNITED STATES USING THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS)
A RETROSPECTIVE ANALYSIS OF PATIENT-REPORTED OUTCOMES AND OTHER EFFICACY ENDPOINTS IN TOP BRAND NAME PRODUCT LABELS IN UNITED STATES
A COMPARISON OF CLINICAL TRIAL PARTICIPANTS TO THE GENERAL PATIENT POPULATION IN FRANCE, GERMANY AND UK
PRINCIPAL COMPONENT ANALYSIS OF A PATIENT SATISFACTION OF CARE SURVEY AND THE RELATIONSHIP BETWEEN PRINCIPAL COMPONENTS AND OVERALL SATISFACTION
USE OF PRO INSTRUMENTS
HOW GOOD IS GOOD ENOUGH? INTERNAL VALIDITY OF STATED PREFERENCES FOR DRUG THERAPIES
CROSS-OVER RANDOMIZED CONTROL TRIAL OF ELECTRONIC MEASUREMENT OF HEALTH-RELATED QUALOITY OF LIFE IN CHINA
FEASIBILITY, VALIDITY AND RELIABILITY OF THE WELSH VERSION OF THE EQ-5D HEALTH STATUS QUESTIONNAIRE
TRADING HEALTH VALUES IN CHILE AND THE US USING EQ-5D
CONSISTENCY OF MINIMAL IMPORTANT DIFFERENCES FOR MAPPED UTILITY INSTRUMENTS IN FOUR MAJOR PATIENT GROUPS
PSYCHOMETRIC EVALUATION OF INSTRUMENTS USED TO MEASURE PATIENT SATISFACTION WITH PHARMACIST SERVICES
A MEDIAN MODEL OF US EQ-5D HEALTH STATE PREFERENCES
EFFECT OF CHRONIC DISEASES ON HEALTH SERVICES UTILIZATION
EFFECT OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) ON THE HEALTH SERVICE UTILIZATION FOR PATIENTS WITH CHRONIC DISEASES
JUSTIFYING THE USE OF COST MINIMIZATION ANALYSIS
ICER VS. IERC
GUIDELINES FOR BUDGET IMPACT ANALYSIS IN CANADA
PROPOSAL FOR A METHODOLOGICAL CHANGE OF PRACTISE
SYSTEMATIC BIAS BETWEEN INTERNET AND MAIL SURVEYS
PHARMACOECONOMICS IN THE HEALTH CARE SYSTEM IN GAUTENG PROVINCE
AN APPLICATION OF ITEM RESPONSE THEORY TO PRESCRIBERS' KNOWLEDGE AND ATTITUDE MEASUREMENT
THE ISSUES THAT ARISE DURING THE TRANSLATION OF IVRS (INTERACTIVE VOICE RESPONSE SYSTEM) EPRO SCRIPTS
SIX SIGMA AND LEAN INTEGRATED METHODOLOGIES IN HEALTH CARE TO IMPROVE PATIENT QUALITY OF LIFE
REVIEWING THE REIMBURSEMENT STATUS OF PHARMACEUTICALS—EXPERIENCES FROM SWEDEN
COST CONTROL FOR MENTAL HEALTH
APPLICATION OF COST-EFFECTIVENESS ANALYSIS TO EVALUATE THE PROPOSED FORMULARY STATUS OF A NOVEL ANTIDIABETIC DRUG IN A U.S. COMMERCIAL HEALTH PLAN
IMPLEMENTATION AND EVALUATION OF AN EVIDENCE-BASED CONTINUUM FOR HIP AND KNEE REPLACEMENTS IN ALBERTA
OUTCOMES RESEARCH FOR MILITARY VACCINATION POLICY
INCORPORATION OF COST EFFECTIVENESS FOR FORMULARY ADDITIONS AT A CANCER CENTER
APPLICATION OF PHARMACOECONOMICS TO DOD'S ANTILIPIDEMIC-1 UNIFORM FORMULARY DECISION
EVALUATION OF LEVALBUTEROL USE IN A >600 BED TEACHING HOSPITAL
USING OUTCOMES RESEARCH TO SUPPORT ANITBIOTIC SELECTION
DIVERSITY OF ANTIBIOTIC USE AND BACTERIAL RESISTANCE
APPLIED PHARMACOECONOMICS IN ACADEMIC MEDICINE
CLINICAL OUTCOMES ASSESSMENT IN BEHAVIORAL HEALTH CARE
INCLUDING A PHARMACOECONOMIC MODEL IN THE FORMULARY REVIEW PROCESS OF NEW
POLYPHARMACY MEDICATION THERAPY MANAGEMENT PROGRAM (MTMP) CASE STUDY
MANAGEMENT OF INAPPROPRIATE USE OF GROWTH HORMONE
SHOULD GENETIC TESTING BE USED TO GUIDE WARFARIN THERAPY?
SYNAGIS 2005--2006 SEASON
DETERMINING THE VALUE OF DIAGNOSTIC/GENETIC TESTING TO INFORM HEALTH PLAN DECISION MAKING
OTC PROGRAM FOR COMMON, ROUTINE AILMENTS DESIGNED TO LOWER THE BURDEN ON PROVIDERS AND TO SUBSTITUTE LESS EXPENSIVE OTC MEDICATIONS FOR MORE COSTLY PRESCRIPTION MEDICATIONS